Month: March 2020

Pharma

Lilly Signs a Worldwide License and Research Agreement with Sitryx

Shots: Sitryx to receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies, including Sitryx’s two lead projects The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be […]Read More

Regulatory

AstraZeneca’s Lokelma Receives CHMP’s Recommendation for Approval for Patients with

Shots: The EMA’s CHMP has adopted a positive opinion on a dosing and administration label update for AstraZeneca’s Lokelma to include patients with hyperkalemia on stable hemodialysis The recommendation is based on P-IIIb DIALIZE study assessing Lokelma (qd) vs PBO in 196 patients on non-dialysis days for 8wks. The study demonstrated that patients-maintained pre-dialysis potassium […]Read More

Biotech COVID-19

Johnson & Johnson and BARDA to Fund ~$1B in Research

Shots: The collaboration follows the existing partnership b/w J&J and BARDA while the company expects to initiate the clinical studies of selected vaccine candidates by Sept’2020 with the anticipated first batch of COVID-19 vaccine to be available for EUA in early 2021 Under the new agreement, J&J and BARDA to invest ~1B in research, development […]Read More

Insights+

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where […]Read More